Show simple item record

dc.contributor.authorCoutinho, Lucia H
dc.contributor.authorBrereton, M L
dc.contributor.authorSantos, A M
dc.contributor.authorRyder, W David J
dc.contributor.authorChang, James
dc.contributor.authorHarrison, Christine J
dc.contributor.authorYin, J A
dc.contributor.authorDexter, T Michael
dc.contributor.authorTesta, Nydia G
dc.date.accessioned2010-04-06T11:47:39Z
dc.date.available2010-04-06T11:47:39Z
dc.date.issued1996-06
dc.identifier.citationEvaluation of cytogenetic conversion to Ph- haemopoiesis in long-term bone marrow culture for patients with chronic myeloid leukaemia on conventional hydroxyurea therapy, on pulse high-dose hydroxyurea and on interferon-alpha. 1996, 93 (4):869-77 Br. J. Haematol.en
dc.identifier.issn0007-1048
dc.identifier.pmid8703819
dc.identifier.doi10.1046/j.1365-2141.1996.d01-1733.x
dc.identifier.urihttp://hdl.handle.net/10541/95703
dc.description.abstractLong-term bone marrow culture (LTBMC) has been used successfully in autologous transplantation in chronic myeloid leukaemia (CML). However, variation between patients in the recovery of Ph- cells in culture limits the application of this procedure to a minority. Treatment that effectively reduces in vivo tumour burden prior to initiation of LTBMC may improve the selection of Ph- cells in culture. To test this hypothesis we evaluated the frequency and degree of cytogenetic conversion to Ph- haemopoiesis in LTBMC from four independent groups of CML patients: Untreated (n = 19); conventional dosage of hydroxyurea (HU) (n = 10); pulse high-dose HU (P-HU) (n = 22) and interferon (IFN)-alpha (n = 12). In this study IFN-alpha therapy resulted in a significantly higher incidence of patients with detectable Ph- clonogenic cells in the marrow (P = 0.01) and with > or = 50% Ph- haemopoiesis in LTBMC as compared to newly diagnosed patients (P = 0.05). Also, sequential culture studies undertaken in 14 CML patients at diagnosis and following the start of pulse highdose HU therapy showed that in eight patients the average proportion of Ph- metaphases detected in LTBMC substantially increased from 1.7% (range 0-7) at diagnosis to levels of 71% (range 14-100) after treatment. Therefore we conclude that the use of IFN or pulse high-dose HU in early stage disease appears to create an opportunity to harvest the marrow for long-term culture (LTC) purging with reduced leukaaemic burden.
dc.language.isoenen
dc.subjectHaematopoiesisen
dc.subjectLeukaemiaen
dc.subjectCultured Tumour Cellsen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshBone Marrow
dc.subject.meshFemale
dc.subject.meshHematopoiesis
dc.subject.meshHumans
dc.subject.meshHydroxyurea
dc.subject.meshInterferon-alpha
dc.subject.meshLeukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshTumor Cells, Cultured
dc.titleEvaluation of cytogenetic conversion to Ph- haemopoiesis in long-term bone marrow culture for patients with chronic myeloid leukaemia on conventional hydroxyurea therapy, on pulse high-dose hydroxyurea and on interferon-alpha.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Experimental Haematology, Christie Hospital NHS Trust, Manchester.en
dc.identifier.journalBritish Journal of Haematologyen
html.description.abstractLong-term bone marrow culture (LTBMC) has been used successfully in autologous transplantation in chronic myeloid leukaemia (CML). However, variation between patients in the recovery of Ph- cells in culture limits the application of this procedure to a minority. Treatment that effectively reduces in vivo tumour burden prior to initiation of LTBMC may improve the selection of Ph- cells in culture. To test this hypothesis we evaluated the frequency and degree of cytogenetic conversion to Ph- haemopoiesis in LTBMC from four independent groups of CML patients: Untreated (n = 19); conventional dosage of hydroxyurea (HU) (n = 10); pulse high-dose HU (P-HU) (n = 22) and interferon (IFN)-alpha (n = 12). In this study IFN-alpha therapy resulted in a significantly higher incidence of patients with detectable Ph- clonogenic cells in the marrow (P = 0.01) and with > or = 50% Ph- haemopoiesis in LTBMC as compared to newly diagnosed patients (P = 0.05). Also, sequential culture studies undertaken in 14 CML patients at diagnosis and following the start of pulse highdose HU therapy showed that in eight patients the average proportion of Ph- metaphases detected in LTBMC substantially increased from 1.7% (range 0-7) at diagnosis to levels of 71% (range 14-100) after treatment. Therefore we conclude that the use of IFN or pulse high-dose HU in early stage disease appears to create an opportunity to harvest the marrow for long-term culture (LTC) purging with reduced leukaaemic burden.


This item appears in the following Collection(s)

Show simple item record